Label: information for the patient
Jardiance 10mg film-coated tablets
Jardiance 25mg film-coated tablets
empagliflozina
Read this label carefully before starting to take this medicine, as it contains important information for you.
What is Jardiance
Jardiance contains the active ingredient empagliflozina.
Jardiance is a member of a group of medicines known as sodium-glucose cotransporter 2 (SGLT2) inhibitors.
What is Jardiance used for
Type 2 diabetes
Jardiance works by blocking the SGLT2 protein in the kidneys. This causes the removal of sugar (glucose) from the blood in the urine. As a result, Jardiance reduces the amount of sugar in the blood.
This medicine may also help prevent heart disease in patients with type 2 diabetes.
It is essential to follow the diet and exercise plan recommended by your doctor, pharmacist, or nurse.
Heart failure
Chronic kidney disease
What is type 2 diabetes?
Type 2 diabetes is a condition that results from a combination of genetic and lifestyle factors. If you have type 2 diabetes, your pancreas does not produce enough insulin to control the level of glucose in your blood, and your body is unable to use its own insulin effectively. This leads to high levels of glucose in your blood, which can cause serious health problems such as heart disease, kidney disease, blindness, and poor circulation in your limbs.
What is heart failure?
Heart failure occurs when the heart is too weak or stiff and cannot function properly. This can cause serious health problems and may require hospital care. The most common symptoms of heart failure are shortness of breath (dyspnea), persistent or intense fatigue, and swelling of the ankles.
Jardiance helps protect your heart from further weakening and improves symptoms.
What is chronic kidney disease?
Chronic kidney disease is a long-term condition. It may be caused by other diseases such as diabetes and high blood pressure or even by the patient's immune system attacking the kidneys. When you have chronic kidney disease, your kidneys may gradually lose their ability to clean and filter your blood properly. This can cause serious health problems such as swollen legs, heart failure, or the need for hospital care.
Jardiance helps protect your kidneys from losing their function.
Do not take Jardiance
-if you are allergic to empagliflozin or any of the other ingredients of this medicine (listed in section 6).
Warnings and precautions
Seek medical attention immediately:
Cetoacidosis
If you suspect you have cetoacidosis, seek medical attention immediately and stop taking this medicine until you speak with your doctor.
Consult your doctor, pharmacist, or nurse before starting to take this medicine and during treatment:
The possible signs are included in section 4 in the subsection “dehydration”. Your doctor may ask you to stop taking Jardiance until you recover to prevent excessive fluid loss. Ask how to prevent dehydration.
Seek medical attention immediately if you experience a combination of symptoms such as pain, tenderness, redness, or inflammation of the genitals or the area between the genitals and the anus, with fever or general discomfort. These symptoms may be a sign of a rare but serious, even potentially life-threatening, condition called necrotizing fasciitis of the perineum or Fournier's gangrene, which destroys tissue under the skin. Fournier's gangrene requires immediate treatment.
Foot care
As with all diabetic patients, it is essential to regularly inspect your feet and follow all foot care advice provided by your healthcare professional.
Kidney function
Your kidney function should be checked before starting this medicine and during treatment with it.
Urine glucose
Due to how this medicine works, your urine will test positive for glucose while you are taking this medicine.
Children and adolescents
Jardiance can be used in children aged 10 years or older for the treatment of type 2 diabetes. There are no data available for children under 10 years of age.
Jardiance is not recommended for children and adolescents under 18 years of age for the treatment of heart failure or for the treatment of chronic kidney disease because it has not been studied in these patients.
Other medicines and Jardiance
Inform your doctor or pharmacist if you are taking, have taken recently, or may need to take any other medicine.
It is essential to inform your doctor in the following cases:
Pregnancy and breastfeeding
If you are pregnant or breastfeeding, or if you think you may be pregnant, consult your doctor or pharmacist before using this medicine. Do not use Jardiance if you are pregnant. The safety of Jardiance for the fetus is unknown. Do not use Jardiance if you are breastfeeding. The safety of Jardiance for the baby is unknown.
Driving and operating machines
The influence of Jardiance on your ability to drive and operate machines is small.
Taking this medicine in combination with medicines called sulfonilureas or with insulin may cause your blood glucose levels to drop too low (hypoglycemia), which can cause symptoms such as shakiness, sweating, and changes in vision that may affect your ability to drive and operate machines. Do not drive or use tools or machines if you feel dizzy while taking Jardiance.
Jardiance contains lactose
Jardiance contains lactose (milk sugar). If your doctor has told you that you have a certain sugar intolerance, consult with them before taking this medicine.
Jardiance contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per tablet; it is essentially “sodium-free”.
Follow exactly the administration instructions of this medication as indicated by your doctor. In case of doubt, consult your doctor or pharmacist again.
How much to take
How to take this medication
If you have type 2 diabetes, your doctor may prescribe Jardiance along with another diabetes medication. Remember to take all your medications as directed by your doctor to achieve the best results for your health.
A healthy diet and exercise help your body use your blood glucose better. It is essential to follow the diet and exercise plan recommended by your doctor while taking Jardiance.
If you take more Jardiance than you should
If you take more Jardiance than you should, consult a doctor immediately or go to the hospital. Bring the medication packaging with you.
If you forget to take Jardiance
If you forget to take a tablet, what to do depends on the time left until the next dose.
If you interrupt treatment with Jardiance
Do not interrupt treatment with Jardiance without consulting your doctor first, unless you suspect you have ketoacidosis (see "Ketoacidosis" in "Warnings and precautions"). If you have type 2 diabetes, your blood glucose levels may increase if you interrupt treatment with Jardiance.
If you have any other questions about the use of this medication, ask your doctor, pharmacist, or nurse.
Like all medicines, this medicine can cause side effects, although not everyone will experience them.
Get in touch with a doctor or the nearest hospital immediately if you experience any of the following side effects:
Severe allergic reaction, observed infrequently (may affect up to 1 in 100 people)
The possible signs of a severe allergic reaction may include:
Cetoacidosis, observed infrequently (may affect up to 1 in 100 people)
These are the signs of cetoacidosis (see also section 2 “Warnings and precautions”):
This can occur regardless of your blood glucose level. Your doctor may decide to temporarily or permanently discontinue treatment with Jardiance.
Get in touch with your doctor as soon as possible if you experience the following side effects:
Low blood glucose (hypoglycemia), observed very frequently (may affect more than 1 in 10 people)
If you take Jardiance with another medicine that can cause low blood glucose, such as a sulfonylurea or insulin, the risk of low blood glucose is higher. The signs of low blood glucose include:
Your doctor will instruct you on how to treat low blood glucose and what to do if you experience any of the above symptoms. If you have symptoms of low blood glucose, take glucose tablets, eat a high-glucose snack, or drink fruit juice.
Measure your blood glucose if possible and rest.
Urinary tract infection, observed frequently (may affect up to 1 in 10 people)
The signs of a urinary tract infection are:
The urgency to urinate or urinate more frequently may be due to the way Jardiance works, but may also be signs of a urinary tract infection. If you experience an increase in these symptoms, get in touch with your doctor.
Dehydration, observed very frequently (may affect more than 1 in 10 people)
The signs of dehydration are not specific, but may include:
Other side effects while taking Jardiance:
Frequent
Infrequent
Rare
Very rare
Reporting side effects
If you experience any type of side effect, consult your doctor, pharmacist, or nurse, even if it is a possible side effect that does not appear in this leaflet. You can also report them directly through thenational notification system included in theAppendix V. By reporting side effects, you can contribute to providing more information on the safety of this medicine.
Keep this medication out of the sight and reach of children.
Do not use this medication after the expiration date that appears on the blister pack and on the box after “CAD”. The expiration date is the last day of the month indicated.
This medication does not require special storage conditions.
Do not use this medication if you observe that the packaging is damaged or shows visible signs of manipulation.
Medications should not be disposed of through drains or in the trash. Ask your pharmacist how to dispose of the containers and medications that you no longer need. This will help protect the environment.
Composition of Jardiance
Appearance of the product and contents of the pack
Jardiance 10 mg film-coated tablets are round, pale yellow, biconvex, and have a beveled edge. They are engraved with the inscription "S10" on one face and the Boehringer Ingelheim logo on the other. The tablets measure 9.1 mm in diameter.
Jardiance 25 mg film-coated tablets are oval, pale yellow, and biconvex. They are engraved with the inscription "S25" on one face and the Boehringer Ingelheim logo on the other. The tablet measures 11.1 mm in length and 5.6 mm in width.
Jardiance tablets are available in perforated unit dose blisters of PVC/aluminium. The pack sizes are 7 x 1, 10 x 1, 14 x 1, 28 x 1, 30 x 1, 60 x 1, 70 x 1, 90 x 1, and 100 x 1 film-coated tablets.
Only some pack sizes may be marketed in your country.
Marketing Authorisation Holder
Boehringer Ingelheim International GmbH
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Responsible for manufacturing
Boehringer Ingelheim Pharma GmbH & Co. KG
Binger Strasse 173
55216 Ingelheim am Rhein
Germany
Boehringer Ingelheim Hellas Single Member S.A.
5th km Paiania – Markopoulo
Koropi Attiki, 19441
Greece
Rottendorf Pharma GmbH
Ostenfelder Strasse 51 – 61
59320 Ennigerloh
Germany
Boehringer Ingelheim France
100-104 Avenue de France
75013 Paris
France
You can request more information about this medicine by contacting the local representative of the marketing authorisation holder:
België/Belgique/Belgien Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 | Lietuva Boehringer Ingelheim RCV GmbH & Co KG Lietuvos filialas Tel.: +370 5 2595942 |
Luxembourg/Luxemburg Boehringer Ingelheim SComm Tél/Tel: +32 2 773 33 11 | |
Ceská republika Boehringer Ingelheim spol. s r.o. Tel: +420 234 655 111 | Magyarország Boehringer Ingelheim RCV GmbH & Co KG Magyarországi Fióktelepe Tel.: +36 1 299 89 00 |
Danmark Boehringer Ingelheim Danmark A/S Tlf: +45 39 15 88 88 | Malta Boehringer In gelheim Ireland Ltd. Tel: +353 1 295 9620 |
Deutschland Boehringer Ingelheim Pharma GmbH & Co. KG Tel: +49 (0) 800 77 90 900 Lilly Deutschland GmbH Tel. +49 (0) 6172 273 2222 | Nederland Boehringer Ingelheim B.V. Tel: +31 (0) 800 22 55 889 |
Eesti Boehringer Ingelheim RCV GmbH & Co KG Eesti filiaal Tel: +372 612 8000 | Norge Boehringer Ingelheim Danmark Norwegian branch Tlf: +47 66 76 13 00 |
Ελλάδα Boehringer Ingelheim Ελλ άς Μονοπρóσωπη A.E. Tηλ: +30 2 10 89 06 300 | Österreich Boehringer Ingelheim RCV GmbH & Co KG Tel: +43 1 80 105-7870 |
España Boehringer Ingelheim España, S.A. Tel: +34 93 404 51 00 | Polska Boehringer Ingelheim Sp.zo.o. Tel.: +48 22 699 0 699 |
France Boehringer Ingelheim France S.A.S. Tél: +33 3 26 50 45 33 | Portugal Boehringer Ingelheim Portugal, Lda. Tel: +351 21 313 53 00 |
Hrvatska Boehringer Ingelheim Zagreb d.o.o. Tel: +385 1 2444 600 | România Boehringer Ingelheim RCV GmbH & Co KG Viena - Sucursala Bucuresti Tel: +40 21 302 28 00 |
Ireland Boehringer Ingelheim Ireland Ltd. Tel: +353 1 295 9620 | Slovenija Boehringer Ingelheim RCV GmbH & Co KG Podružnica Ljubljana Tel: +386 1 586 40 00 |
Ísland Vistor ehf. Sími: +354 535 7000 | Slovenská republika Boehringer Ingelheim RCV GmbH & Co KG organizacná zložka Tel: +421 2 5810 1211 |
Italia Boehringer Ingelheim Italia S.p.A. Tel: +39 02 5355 1 | Suomi/Finland Boehringer Ingelheim Finland Ky Puh/Tel: +358 10 3102 800 |
Κύπρος Boehringer Ingelheim Ελλ άς Μονοπρóσωπη A.E. Tηλ: +30 2 10 89 06 300 | Sverige Boehringer Ingelheim AB Tel: +46 8 721 21 00 |
Latvija Boehringer Ingelheim RCV GmbH & Co KG Latvijas filiale Tel: +371 67 240 011 | United Kingdom (Northern Ireland) Boehringer Ingelheim Ireland Lt d. Tel: +353 1 295 9620 |
Last update of this leaflet: {MM/AAAA}.
The detailed information on this medicine is available on the website of the European Medicines Agency:
http://www.ema.europa.eu.Есть вопросы по этому лекарству или вашим симптомам? Свяжитесь с лицензированным врачом для получения помощи и персонализированного ухода.